This clinical trial is for with men with metastatic castration-resistant prostate cancer (mCRPC) and is trying to find out if combining pembrolizumab and enzalutamide can slow down prostate cancer.

Why is this study being done?

This study is trying to find out if an investigational medication in combination with enzalutamide is safe and works to slow down or stop the growth of mCRPC compared to enzalutamide alone. Researchers don’t know if this combination of drugs works to treat this type of cancer.

The treatment being studied:

This clinical trial is studying an investigational medication called Pembrolizumab (also known as MK-3475) in combination with enzalutamide. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This immunotherapy is FDA approved to treat other types of cancer but is not approved to treat mCRPC. Before deciding to participate, you should make sure you understand the potential side effects or risks of participating in the study. These will be explained to you by the study doctor. If there is anything you do not understand; you are encouraged to ask the study doctor.

For more information, click here.

Organization: Merck

If you are interested in this trial, review the following:

• ClinicalTrials.gov Identifier: NCT03834493
• Merck Prostate Cancer Clinical Trial: KEYNOTE 641
• Trial Contact and Locations
• Use the “clinical trials glossary” and “dictionary” for words, phrases and treatments that you may not understand.

Register your interest or comments about this trial with PHEN

PHEN Contact: 617-481-4020*

Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.

Go Back